Sutro Biopharma Profit Margin

The latest profit margin for STRO is -395.25% as of June 2026. That compares with -199.76% in the prior-year period — down 97.9% year over year. That is below the Healthcare sector average of 13.39%. Investors often review this figure alongside Sutro Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, STRO's profit margin moved from -199.76% to -395.25% — a 97.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sutro Biopharma's valuation or profitability profile.

Against Healthcare companies, STRO currently prints -395.25% for profit margin, while the sector average sits near 13.39%. That is roughly 3052.7% below the sector mean. Large gaps often invite a closer look at Sutro Biopharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Sutro Biopharma converts resources into returns. At -395.25%, STRO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -199.76% in the prior-year period — down 97.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting STRO's profit margin (-395.25%), review year-over-year change from -199.76%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.